Biocon and its subsidiary -- Biocon Biologics -- have activated business continuity plans across their functions to prepare for unforeseen events in light of the evolving COVID19 situation and to meet the needs of patients, partners, customers and other stakeholders who depend on their products.
The government of India has announced a 21-day nationwide lockdown on March 24, 2020, but permitted ‘essential services’ such as manufacturing of pharmaceuticals to continue. The company will continue to operate essential pharmaceutical manufacturing in full compliance with government requirements.
Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation-driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.
